

This item was submitted to Loughborough's Institutional Repository (<https://dspace.lboro.ac.uk/>) by the author and is made available under the following Creative Commons Licence conditions.



CC creative commons
COMMONS DEED

Attribution-NonCommercial-NoDerivs 2.5

You are free:

- to copy, distribute, display, and perform the work

Under the following conditions:

 **Attribution.** You must attribute the work in the manner specified by the author or licensor.

 **Noncommercial.** You may not use this work for commercial purposes.

 **No Derivative Works.** You may not alter, transform, or build upon this work.

- For any reuse or distribution, you must make clear to others the license terms of this work.
- Any of these conditions can be waived if you get permission from the copyright holder.

Your fair use and other rights are in no way affected by the above.

This is a human-readable summary of the [Legal Code \(the full license\)](#).

[Disclaimer](#) 

For the full text of this licence, please go to:
<http://creativecommons.org/licenses/by-nc-nd/2.5/>

1 Deborah K Fletcher and Nicolette C Bishop

2

3 Effect of a single and repeated dose of caffeine on antigen-stimulated human natural killer

4 cell CD69 expression after high intensity intermittent exercise

5

6 School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough,

7 Leicestershire, LE11 3TU, UK

8

9 Address for correspondence:

10

11 Nicolette C Bishop

12 School of Sport, Exercise and Health Sciences

13 Loughborough University

14 Loughborough

15 Leicestershire

16 LE11 3TU

17 UK

18

19 Email: N.C.Bishop@lboro.ac.uk

20 Tel: +44 1509 226385

21 Fax: +44 1509 226301

22

23

24

25

26 **Abstract**

27 Several studies investigating the effect of caffeine on immune function following exercise
28 have used one large bolus dose of caffeine. However, this does not model typical caffeine
29 consumption. Therefore the purpose of this study was to investigate whether small repeated
30 doses of caffeine ingested throughout the day would elicit a similar response as one large
31 bolus dose ingested 1 h prior to exercise on antigen-stimulated NK cell CD69 expression
32 following strenuous intermittent exercise. In a randomized cross-over design, 15 healthy
33 males completed six 15 min blocks of intermittent running consisting of maximal sprinting
34 interspersed with less intense running and walking. Participants had ingested either 0 (PLA),
35 2 mg·kg⁻¹ body mass (BM) caffeine on 3 separate occasions during the day (3xCAF) or 1
36 dose of 6 (1xCAF) mg·kg⁻¹ BM caffeine, 1 h before exercise. At 1 h post-exercise the
37 number of antigen-stimulated CD3⁺CD56⁺ cells expressing CD69 was lower on 1xCAF
38 compared with PLA [P<0.05; PLA: 42.0 (34.0)x10⁶ cells·L⁻¹, 1xCAF: 26.2 (25.0)x10⁶
39 cells·L⁻¹], with values on 1xCAF at this time-point remaining close to pre-supplement.
40 1xCAF tended to attenuate the exercise-induced increase in geometric mean fluorescence
41 intensity of CD69 expression on antigen-stimulated CD3⁺CD56⁺ cells 1 h post-exercise
42 [P=0.055; PLA: 141 (28)%, 1xCAF: 119 (20)%]. These findings suggest that although one
43 large bolus dose of caffeine attenuated the exercise-induced increase in antigen-stimulated
44 NK cell CD69 expression 1 h following strenuous intermittent exercise, this attenuation at no
45 point fell below pre-supplement values and as such caffeine does not appear to depress NK
46 cell CD69 expression.

47

48

49 **Keywords:** methylxanthine, CD69, exercise, immune, lymphocyte

50

51

52

53

54

55

56

57 **Introduction**

58 Caffeine is a common element in most people's diets (Heatherley et al. 2006), yet it is not a
59 typical nutrient nor is it essential for health (Graham 2001). Caffeine is legally and socially
60 acceptable and as such is the most widely consumed behaviour-influencing substance in the
61 world (Graham 2001). It is estimated that the mean daily intake of caffeine in the U.K is
62 $\sim 241 \pm 173 \text{ mg}\cdot\text{day}^{-1}$, which is the equivalent to around 2-4 cups of coffee (Heatherley et al.
63 2006). However, daily caffeine intake can vary widely depending upon country. For example
64 the daily caffeine intake in Sweden, Norway and Netherlands is estimated to be
65 approximately $400 \text{ mg}\cdot\text{day}^{-1}$ (Fredholm et al. 1999).

66

67 Natural killer (NK) cells are a subset of lymphocytes that have innate immune functions,
68 representing approximately 5–20 % of all lymphocytes in peripheral blood (Andoniou et al.
69 2006). NK cells are capable of recognizing and destroying certain tumour cells and virally-
70 infected cells without prior sensitization or specific antigen recognition, and therefore are
71 distinct from other lymphocytes. At rest (unstimulated) NK cells tend to express small
72 amounts of functionally active CD69 (Borrego et al. 1999), however following activation this
73 antigen is rapidly induced (Ziegler 1994). Although the exact role of CD69 has not as yet
74 been elucidated, *in vitro* studies have demonstrated that once expressed on lymphocytes, this
75 antigen appears to act as a co-stimulatory receptor helping to trigger subsequent cell
76 proliferation, cytotoxicity and secretion of cytokines (such as tumour necrosis factor- α and
77 interferon- γ) (Borrego et al. 1999). However, *in vivo* studies have demonstrated that the
78 behaviour of CD69 is more complex, and also appears to act as an immunoregulatory
79 molecule (reviewed in Sancho et al. 2005). Several studies have demonstrated that CD69
80 cross-linking appears to induce the production of the anti-inflammatory cytokine transforming

81 growth factor- β (TGF- β) in lymphocytes, that appears to be able to downregulate the
82 inflammatory response as well as tumour lysis by NK cells (Esplugues et al. 2003; Sancho et
83 al. 2003).

84

85 Acute strenuous exercise causes a temporary perturbation in a range of immune cell functions
86 usually lasting between ~3-24 h. It is suggested that during this “open window” of altered
87 immunity, viruses and bacteria may gain a foothold, increasing the risk of subsequent
88 infection (Nieman 2000). Several studies have demonstrated that for several hours following
89 both high intensity continuous and intermittent exercise NK cell number and function are
90 suppressed to below baseline measures (Kappel et al. 1991; McFarlin et al. 2004; Neiman et
91 al. 2007). NK cells express both adenosine receptors (A_1 , A_{2A} and A_{2B}) and β_2 -
92 adrenoreceptors (Priebe et al. 1990; Shephard 2003). Caffeine is a non-selective adenosine
93 receptor antagonist and also stimulates epinephrine release from the adrenal medulla; as such
94 caffeine has the potential to either increase (via A_{2A} receptor antagonism) or decrease (via A_1
95 receptor antagonism and/or increased epinephrine stimulation) NK cell activation depending
96 upon the principal mechanism. Strenuous exercise increases the plasma concentrations of both
97 adenosine and epinephrine (Nieman et al. 2007; Vizi et al. 2002) and it has been proposed that
98 these increases predominately inhibit NK cell function *in vitro* and *in vivo* (Kappel et al.
99 1991; Priebe et al. 1990), via A_{2A} adenosine receptor and β_2 -adrenoreceptor activation of
100 adenylate cyclase and increased intracellular cAMP (Raskovalova et al. 2006). It is likely that
101 in response to caffeine ingestion and exercise both adenosine and epinephrine mechanisms
102 will be involved. However, the overall affect on NK cell activation may depend upon which
103 mechanism predominates.

104

105 Caffeine has been shown to increase sympathoadrenal medullary system (SAM) activity and
106 as such plasma epinephrine concentration (reviewed in Graham 2001). Salivary α -amylase
107 activity is stimulated by increased activity of the sympathetic nervous system (Rohleder et al.
108 2004). Therefore, it has been suggested that elevations in α -amylase concentration can be
109 considered a good indicator of enhanced sympathetic activity (Anderson et al. 1984; Rohleder
110 et al. 2004). As such salivary α -amylase has been chosen as a surrogate marker for plasma
111 epinephrine concentration in the present study.

112

113 Despite the reported widespread and frequent use of caffeine within society (Heatherley et al.
114 2006), very few studies have investigated the effect of caffeine on immune cell responses to
115 exercise in healthy individuals. Of the handful of studies that have been published, all have
116 administered $6 \text{ mg}\cdot\text{kg}^{-1}$ body mass caffeine in one bolus dose following a 60 h abstinence
117 period (Bishop et al. 2005, 2006; Fletcher and Bishop 2010; Walker et al. 2006, 2007, 2008).
118 However, caffeine is typically consumed in separate doses throughout the day, following an
119 overnight abstention (Fredholm et al. 1999). To the authors knowledge no study to date has
120 attempted to model natural caffeine consumption in terms of dose and time of consumption
121 when investigating caffeine's effects on immune cell function following exercise. Recent
122 pilot work from our group has suggested that a small dose of caffeine ($2 \text{ mg}\cdot\text{kg}^{-1}$) ingested
123 prior to exercise increases antigen-stimulated NK cell CD69 expression 1 h following high
124 intensity cycling to the same extent as that of a dose 3 times as large ($6 \text{ mg}\cdot\text{kg}^{-1}$). Therefore
125 the aim of this study was to investigate whether small repeated doses ($2 \text{ mg}\cdot\text{kg}^{-1}$) of caffeine
126 ingested throughout the day (9:00 h, 12:00 h & 15:00 h) would elicit a similar response as one
127 large ($6 \text{ mg}\cdot\text{kg}^{-1}$) bolus dose ingested 1 h prior to exercise (15:00 h) compared with placebo
128 on antigen-stimulated NK cell CD69 expression following 90 min of high intensity
129 intermittent exercise. It was hypothesised that both caffeine trials would increase NK cell

130 CD69 expression to a similar extent following high intensity intermittent exercise, and that
131 this increase would be significantly greater when compared with placebo.

132

133 **Methods**

134 *Participants*

135 Fifteen healthy male games (football and rugby) players [mean (SD): age 22 (2) years; body
136 mass 76 (8) kg; $\dot{V}O_{2\max}$ 54 (3) ml·kg⁻¹·min⁻¹] volunteered to participate in this study. All
137 participants were fully informed about the rationale for the study and the design of the
138 exercise tests and trial protocol, along with their possible risks and discomforts, before
139 providing written informed consent. The local Ethical Advisory Committee approved the
140 study. Participants did not report taking any medications or experiencing any symptoms of
141 upper respiratory tract infection in the 4 weeks prior to the study. All participants were
142 moderate caffeine users (50 – 250 mg·day⁻¹), with an average daily caffeine intake of 159 (61)
143 mg·day⁻¹.

144

145 *Preliminary testing*

146 Approximately 2 weeks before the beginning of the main trials, each participant was required
147 to perform a progressive shuttle run test to volitional fatigue to estimate maximal oxygen
148 consumption ($\dot{V}O_{2\max}$) (Ramsbottom et al., 1988). From this estimate, running speeds
149 corresponding to 55% and 95% $\dot{V}O_{2\max}$ were calculated from the tables for predicted $\dot{V}O_{2\max}$
150 values (Ramsbottom et al., 1988). Participants came back into the lab on a separate occasion
151 to undertake a familiarization trial, which required them to perform 3x15 min blocks (45 min)
152 of the LIST. Heart rates (Polar FS1, Polar Electro Oy, Kempele, Finland) were monitored
153 continuously during the familiarization trial.

154

155 *Experimental trial procedures*

156 Participants were instructed to avoid alcohol consumption and strenuous physical activity in
157 the 24 h preceding each experimental trial. Participants were also instructed to stop
158 consuming caffeine from 21:00 h the night before each trial. In an attempt to standardize
159 nutritional status, participants completed a 24 h food diary the day before and the day of the
160 first main trial. Participants were then asked to follow their food diaries for the second and
161 third main trials. Participants performed 3 main exercise trials, each separated by 1 week.
162 Participants were randomly assigned to either the PLA, 1xCAF (1 single dose of $6 \text{ mg}\cdot\text{kg}^{-1}$
163 caffeine) or 3xCAF (3 repeated doses of $2 \text{ mg}\cdot\text{kg}^{-1}$ caffeine) trial and acted as their own
164 controls in a repeated-measures, single-blind, cross-over design. Participants arrived at the
165 laboratory at 08:50 h following an overnight fast of 12 h. After 10 min of resting quietly an
166 initial (pre-supplement) blood sample was obtained from an antecubital forearm vein by
167 venepuncture. Following the blood sample, an initial (09:00 h, pre-supplement) saliva sample
168 was obtained. Participants then ingested 0 (PLA) or 2 (3xCAF) $\text{mg}\cdot\text{kg}^{-1}$ body mass of
169 caffeine powder (BDH Laboratory Supplies, Poole, UK) taken in the form of cellulose
170 capsules (G & G Food Supplies Ltd, West Sussex, UK) with 300 ml plain water. For the 0
171 $\text{mg}\cdot\text{kg}^{-1}$ dose, participants ingested 2 $\text{mg}\cdot\text{kg}^{-1}$ body mass of dextrose powder (BDH
172 Laboratory Supplies, Poole, UK). The specific timings of PLA or CAF ingestion along with
173 blood and saliva samples are illustrated in Fig. 1. Participants then rested quietly in the
174 laboratory for 1 h before a further (10:00 h) saliva sample was taken, after which participants
175 were free to leave the laboratory and to start eating. Participants were required to return to the
176 laboratory at 12:00 h to ingest another set of either 0 (PLA) or 2 (3xCAF) $\text{mg}\cdot\text{kg}^{-1}$ caffeine
177 capsules and to provide a further saliva sample (12:00 h). After the saliva sample participants
178 left the laboratory until 15:00 h, at which time they provided another saliva sample (15:00 h).

179 Participants stopped eating from 15:00 h. Participants then ingested a final set of either 0
180 (PLA), 2 (3xCAF) or 6 (1xCAF) mg·kg⁻¹ caffeine capsules immediately after the saliva
181 sample. Participants then rested quietly in the laboratory for 1 h before a further venous blood
182 and saliva sample (16:00 h, pre-exercise) were taken. Immediately following venous blood
183 and saliva samples pre-exercise body mass (in shorts only) was recorded, after which,
184 participants began six 15 min periods of intermittent shuttle running, which consisted of ~10
185 cycles of walking, maximal sprinting, jogging and cruising (Fig. 2). Participants were
186 required to run between two lines separated by 20 m at various speeds that related to previous
187 $\dot{V}O_{2\max}$ values. Each 15 min bout of running was separated by a 3 min rest period. During
188 this period participants were allowed to consume plain water *ad libitum* and were asked to
189 rate their perceived exertion (RPE) on a Borg 6-20 scale. Heart rates were recorded prior to,
190 during and immediately after each 15 min period of intermittent shuttle running. A further
191 venous blood and saliva sample (17:45 h, post-exercise) was obtained immediately after
192 cessation of exercise, before post-exercise body mass (in shorts only) was recorded.
193 Participants then consumed 5 ml·kg⁻¹ body mass of plain water and rested quietly in the
194 laboratory for a further hour before a final venous blood and saliva sample (18:45 h, 1 h post-
195 exercise) was obtained. During this time no additional food or fluid was administered to
196 participants. For all venous blood samples, 20 ml of blood was obtained, with all samples
197 taken from participants in an upright-seated position. For all saliva samples, participants were
198 asked to swallow to empty the mouth before timed unstimulated whole mixed saliva
199 collections were made into pre-weighed sterile vials (7 ml capacity bijou tubes with screw-
200 top). All collections were made over a 2 min period, unless insufficient volume had been
201 produced, in which case the collection period was increased to 3 min, as necessary. All
202 collections were made with participants seated; leaning forwards and with their heads tilted
203 downwards. Participants were instructed to allow the saliva to dribble into the tube with

204 minimal orofacial movement. Laboratory conditions throughout the study were 20.5 (0.9) °C
205 and 35.7 (5.4) % relative humidity.

206

207 *Total lymphocyte count and plasma volume*

208 Blood samples were collected into two evacuated monovette tubes (Starstedt, Leicester, UK),
209 one containing K₃EDTA (1.6 mg EDTA ml⁻¹ blood) and one containing no additive to obtain
210 serum, as well as a sterile 5 ml bijou tube (Sterilin, Staffordshire, UK) containing 15 µl
211 sodium heparin (15 IU heparin ml⁻¹ blood). Blood collected into the K₃EDTA monovette (7.5
212 ml) was analyzed for total and differential leukocyte counts, hematocrit and hemoglobin
213 contents using a hematology analyzer (A^C.TTM 5diff analyzer, Beckman Coulter, UK).
214 Plasma volume changes were estimated according to Dill and Costill (1974).

215

216 *Lymphocyte culture*

217 Five ml of whole blood transferred into the sterile bijou tube containing heparin was
218 immediately placed on ice and mixed (Thermo Denley, Spiramix) for 20 min before setting
219 up cultures. Due to the large time gap (6 h) between pre-supplement and pre-exercise venous
220 blood samples, 2 lots of cultures were set up: one set was the pre-supplement sample, the
221 other set was the pre-exercise, post-exercise and 1 h post-exercise samples. Cells were
222 cultured in Falcon 12 x 75 mm-polystyrene tubes with caps (Becton Dickinson Biosciences,
223 Oxford, UK) and for all samples stimulated and unstimulated cultures were set up. Tubes
224 were stimulated by a 1:400 or 1:800 Pediacel vaccine (Sanofi Pasteur MSD Ltd, Berkshire,
225 UK), containing diphtheria toxoid, tetanus toxoid, acellular pertussis bacteria, poliovirus and
226 haemophilus influenza type b. Zero or 20 µl of Pediacel working vaccine (either 1:400 or
227 1:800) was added to 200 µl of heparinized whole blood, giving a final stimulant concentration

228 of 1:4000 (optimum) or 1:8000 (sub-optimum) before being incubated for 20 h at 37 °C, 5%
229 CO₂. All cell culture work was carried out in a class II laminar flow hood (Esco GB Ltd,
230 Salisbury, UK) by using aseptic techniques.

231

232 *Assessment of lymphocyte subsets and CD69 expression*

233 After incubation, peripheral blood cells were labelled with a cocktail of Pharmingen
234 monoclonal antibodies (Becton Dickinson Biosciences, Oxford, UK) against human
235 lymphocyte cell surface markers, as follows: 5 µl CD3 FITC, 20 µl CD56 PE-Cy5 and 10 µl
236 CD69 PE. All samples were then vortexed and placed on ice for 20 min, after which
237 erythrocytes were lysed and leukocytes fixed using FACS Lyse (Becton Dickinson, Oxford,
238 UK). Leukocytes were washed once in 3 ml ice cold phosphate-buffered saline (PBS)
239 containing 0.1% bovine serum albumin (BSA) and 2 mM EDTA (PBS/BSA/EDTA) before
240 being resuspended in 400 µl PBS/BSA/EDTA. Three-colour flow cytometric analysis was
241 performed using a FACS Calibur flow cytometer with Cell Quest analysis software (Becton
242 Dickinson, Oxford, UK). Standard gating procedures using side scatter versus forward scatter
243 plots were used to gate on the lymphocyte population. An unstained unstimulated sample was
244 used to set quadrant boundaries to allow accurate acquisition of stained samples. All samples
245 were set to collect 30,000 lymphocyte events per analysis.

246

247 CD3⁺ (T cell region) and CD56⁺ (NK cell region) populations were acquired on quadrant dot
248 plots of FL1 (CD3 FITC) and FL3 (CD56 PE-Cy5), along with quadrant dot plots of FL1
249 (CD3) and FL2 (CD69 PE) and quadrant dot plots of FL3 (CD56) and FL2 (CD69). This data
250 was then displayed as histogram plots and the percentage of CD3⁻ cells (total lymphocyte
251 region minus the CD3⁺ region) expressing CD56⁺ were derived and from this the percentage
252 of total lymphocytes that were CD3⁻CD56⁺ was determined. CD3⁻CD56⁺ cells were then

253 gated into a separate region and a CD69⁺ histogram plot of the cells within this region was
254 used to calculate the percentage expression and geometric mean fluorescence intensity
255 (GMFI) expression of CD69 of CD3⁻CD56⁺ cells. Cell counts of CD3⁻CD56⁺ were calculated
256 by multiplying the percentage of these cells with the absolute lymphocyte count. The number
257 of CD3⁻CD56⁺ cells expressing CD69 were determined by multiplying the percentage of cells
258 expressing CD69 by the total number of CD3⁻CD56⁺ cells. To facilitate intersubject
259 comparisons, pre-exercise, post-exercise and 1 h post-exercise CD69 GMFI were expressed
260 as a percentage of the pre-supplement value, as according to Timmons et al. (2006).

261

262 *Saliva flow rate*

263 Saliva samples were stored in their plastic containers at -80 °C prior to analysis. Saliva
264 volume was estimated by weighing the bijou tubes to the nearest mg before and after saliva
265 collection. Saliva density was assumed to be 1.00 g·ml⁻¹ (Cole and Eastoe 1988) and from
266 this, the saliva flow rate (μl·min⁻¹) was determined by dividing the volume of saliva by the
267 collection time.

268

269 *Saliva α-amylase*

270 Saliva α-amylase activity was measured using a commercially available kit (Infinity™
271 Amylase Liquid Stable Reagent, Thermo Scientific, UK), with proportional reduction of
272 volumes so that the assay could be carried out in a microtitration (96-well) plate. Briefly, 20
273 μl saliva diluted 1:100 with 1.0 mM CaCl₂ was mixed with 180 μl of amylase reagent. The
274 plate was incubated for 1 min at 25°C and then the increase in absorbance at 405 nm was
275 recorded every min for a further 4 min period on an automated plate reader. Purified α-
276 amylase from human saliva (A1031, Sigma) was used as a standard. The secretion rate of α-

277 amylase ($\text{U}\cdot\text{min}^{-1}$) was calculated by multiplying the saliva flow rate by the α -amylase
278 activity. The intra assay coefficient of variation for α -amylase was 1.1%

279

280 *Serum and saliva caffeine concentration*

281 Serum was obtained from whole blood collected into a serum monovette (5.5 ml), which was
282 left to clot for 1 h before being centrifuged at 1500 g for 10 min in a refrigerated centrifuge at
283 4 °C. Saliva samples were transferred into eppendorfs and centrifuged at 12000 rpm for 2 min
284 in a high speed microcentrifuge. Serum and saliva caffeine concentration was determined
285 using a commercially available kit (Emit Caffeine Assay, Dade-Behring, Milton Keynes, UK)
286 on an automatic photometric analyzer (COBAS Miras Plus, Roche Diagnostic Systems,
287 Switzerland). The intra assay coefficient of variation for serum and saliva caffeine
288 concentration was 2.6% and 1.7%, respectively.

289

290 *Statistical analysis*

291 Data in the text, tables and figures are presented as mean values and their standard deviation
292 (\pm SD). The data were examined using a two-factor (trial x time) analysis of variance
293 (ANOVA) with repeated measures design. If the data were not normally distributed,
294 statistical analysis was carried out on the logarithmic transformation of the data. Assumptions
295 of sphericity in the data were checked, and adjustments in the degrees of freedom for the
296 ANOVA were made using the Huynh-Feldt method of correction where appropriate. Any
297 significant data were assessed using Student's paired t -tests with Holm-Bonferroni
298 adjustments for multiple comparisons. Statistical significance for this study was accepted at
299 $P < 0.05$. The observed powers of the reported main and interaction effects are all > 0.8 .

300

301 **Results**

302 *Physiological measurements*

303 There were no differences in ratings of perceived exertion between trials during the test [RPE
304 of 13 (2) for all trials]. Likewise, heart rates were similar between trials during exercise
305 [PLA: 171 (12) beat·min⁻¹, 1xCAF: 175 (13) beat·min⁻¹, 3xCAF: 177 (12) beat·min⁻¹; mean
306 of all recordings].

307

308 *Changes in body mass and plasma volume*

309 After exercise, changes in body mass (corrected for fluid intake) were similar for all trials
310 [PLA: -1.8 (0.3) kg, 1xCAF: -1.8 (0.3) kg, 3xCAF: -1.9 (0.4) kg]. There was no significant
311 time x trial interaction effect for changes in plasma volume relative to the initial blood
312 sample. After exercise plasma volume decreased by 3.3 (4.4) %, 3.4 (6.0) % and 4.8 (6.6) %
313 on the PLA, 1xCAF and 3xCAF trials, respectively.

314

315 *Serum caffeine concentration*

316 A significant time x trial interaction was found for serum caffeine concentration (P<0.01),
317 with higher concentrations at pre (16:00 h), post (17:45 h) and 1 h post-exercise (18:45 h) on
318 both 1xCAF and 3xCAF compared with PLA (P<0.01; Fig. 3). Serum caffeine concentration
319 was also significantly higher on 3xCAF at pre-exercise compared with 1xCAF (P<0.05).
320 However at post-exercise and 1 h post-exercise serum caffeine concentrations on 1xCAF were
321 significantly higher than 3xCAF (both P<0.01; Fig 3).

322

323 *Saliva caffeine concentration*

324 A significant time x trial interaction was found for saliva caffeine concentration ($P<0.01$),
325 with higher concentrations at 10:00 h, 12:00 h, 15:00 h and pre (16:00 h), post (17:45 h) and 1
326 h post-exercise (18:45 h) on 3xCAF compared with PLA ($P<0.01$; Table 1) and at post (17:45
327 h) and 1 h post-exercise (18:45 h) on 1xCAF compared with PLA ($P<0.01$; Table 1). Saliva
328 caffeine concentrations were also higher on 3xCAF at 10:00 h, 12:00 h, 15:00 h and pre-
329 exercise compared with 1xCAF ($P<0.01$; Table 1), but lower than 1xCAF at post and 1 h
330 post-exercise ($P<0.01$; Table 1).

331

332 *Saliva flow rate*

333 Saliva flow rate appeared to increase significantly above pre-supplement (9:00 h) values at
334 10:00 h, 12:00 h, 15:00 h, pre-exercise, post-exercise and 1 h post-exercise (main effect for
335 time: all time points $P<0.01$, except post-exercise $P<0.05$; Table 1). However, when
336 compared against pre-exercise values, saliva flow rate fell significantly at post-exercise (main
337 effect for time: $P<0.01$; Table 1). There were no significant effects of trial/treatment.

338

339 *Saliva α -amylase*

340 A significant time x trial interaction was found for saliva α -amylase activity, which was
341 significantly higher at pre-exercise and 1 h post-exercise on both 1xCAF and 3xCAF
342 compared with PLA ($P<0.05$; Table 1). A significant time x trial interaction was also found
343 for saliva α -amylase secretion rate, which was higher at 1 h post-exercise on 1xCAF
344 compared with PLA ($P<0.05$; Table 1). There were no differences between 1xCAF and
345 3xCAF.

346

347 *Circulating lymphocyte counts and numbers of $CD3^+CD56^+$ cells*

348 There were no time x trial interactions for the number of circulating lymphocytes, but there
349 was a main effect for time ($P<0.01$) with the number of circulating lymphocytes increasing
350 above pre-supplement values at immediately post-exercise ($P<0.01$; Table 2). A significant
351 time x trial interaction was found for the number of $CD3^+CD56^+$ cells within the circulating
352 lymphocyte population ($P<0.01$), with a higher number of $CD3^+CD56^+$ cells found at post-
353 exercise on both 1xCAF and 3xCAF compared with PLA ($P<0.05$; Table 2). There were no
354 differences between 1xCAF and 3xCAF.

355

356 *Number of unstimulated and antigen-stimulated $CD3^+CD56^+$ cells expressing CD69*

357 There were no interaction effects for the number of unstimulated $CD3^+CD56^+$ cells expressing
358 CD69. However there was a main effect for time ($P<0.01$) with the number of $CD3^+CD56^+$
359 cells expressing CD69 increasing significantly above pre-supplement values at pre and post-
360 exercise, only to fall below pre-supplement values at 1 h post-exercise (all $P<0.01$; Fig. 4a).
361 When cells were stimulated there was a significant time x trial interaction effect, with the
362 number of antigen-stimulated (both doses) $CD3^+CD56^+$ cells expressing CD69 lower at 1 h
363 post-exercise on 1xCAF compared with PLA ($P<0.05$); values on 1xCAF at this time-point
364 remained close to pre-supplement (Fig. 4b & c). There were no differences between 3xCAF
365 and PLA or 1xCAF and 3xCAF.

366

367 *Geometric Mean Fluorescence Intensity of CD69 expression on unstimulated and antigen-
368 stimulated $CD3^+CD56^+$ cells*

369 There were no significant interaction effects for the GMFI of CD69 expression on
370 unstimulated $CD3^+CD56^+$ cells. However there was a main effect for time ($P<0.01$), with the
371 GMFI of CD69 expression on unstimulated $CD3^+CD56^+$ cells increasing significantly above

372 pre-supplement values at 1 h post-exercise ($P<0.01$; Fig. 5a). When cells were stimulated
373 there was a significant time x trial interaction effect, with the GMFI of CD69 expression on
374 antigen-stimulated (1:8000) CD3⁻CD56⁺ cells increasing on all trials above pre-supplement
375 values at 1 h post-exercise ($P<0.01$; Fig. 5c). However, values tended to be lower on 1xCAF
376 compared with PLA at this time ($P=0.055$; Fig. 5c). The GMFI of CD69 expression on
377 antigen-stimulated (1:8000) CD3⁻CD56⁺ cells was also significantly lower at immediately
378 post-exercise on 1xCAF compared with both PLA and 3xCAF ($P<0.05$), with values on
379 1xCAF at this time-point remaining close to pre-supplement values (Fig. 5c).

380

381 **Discussion**

382 The main findings of this study suggest that exercise induced an increase in the number of
383 antigen-stimulated NK cells expressing CD69 as well as in the GMFI of CD69 expression on
384 antigen-stimulated NK cells 1 h following 90 min shuttle running that was attenuated after
385 consuming one large bolus dose ($6 \text{ mg}\cdot\text{kg}^{-1}$) of caffeine 1 h before exercise (15:00 h; 1xCAF).
386 In contrast, ingesting small doses ($2 \text{ mg}\cdot\text{kg}^{-1}$) of caffeine throughout the day to model a more
387 typical pattern of caffeine consumption (09:00 h, 12:00 h & 15:00h; 3xCAF) had little effect
388 on antigen-stimulated NK cell CD69 expression.

389

390 It has been suggested that caffeine's main mechanism of action is predominately via A_{2A}
391 adenosine receptor antagonism (Fredholm et al. 1999). As such it was speculated that in the
392 present study both caffeine trials would have increased antigen-stimulated NK cell CD69
393 expression in response to exercise compared with placebo as has previously been found
394 (Fletcher and Bishop 2010). However, this was not the case in this study and as such appears
395 to indicate that in the present study A_{2A} adenosine receptor antagonism was not the

396 predominant mechanism involved. NK cells also possess A₁ adenosine receptors (Priebe et
397 al. 1990). As a non-selective adenosine receptor antagonist, caffeine could have antagonized
398 NK cell A₁ receptors (Fredholm et al. 1999), which may have restricted the increase in
399 antigen-stimulated NK cell CD69 expression on both caffeine trials in response to high
400 intensity intermittent exercise compared with placebo.

401

402 It could be suggested that the large bolus dose of caffeine attenuated the exercise-induced
403 increase in NK cell CD69 expression following high intensity shuttle running via stimulating
404 the release of epinephrine. Epinephrine stimulates β_2 -adrenoreceptors found on NK cells,
405 leading to an increase in intracellular cAMP levels. An increase in the concentration of
406 cAMP in the cell may have interfered with signals that are necessary for adhesion
407 strengthening (Benschop et al. 1997) and as such could have preferentially mobilized a less
408 active subset of NK cells into the circulation following exercise. Epinephrine has also been
409 shown to inhibit CD69 expression on mitogen-stimulated NK cells (Shimamiya et al. 2003)
410 and as such may have been responsible for the lower number of antigen-stimulated NK cells
411 expressing CD69 and GMFI expression of CD69 on antigen-stimulated NK cells following
412 the large single dose caffeine trial compared with placebo 1 h following high intensity shuttle
413 running.

414

415 Although plasma epinephrine concentrations were not directly determined in this study, saliva
416 α -amylase activity and secretion rate were measured as a surrogate marker, as increases in α -
417 amylase concentration are considered a good indicator of enhanced sympathetic activity
418 (Anderson et al. 1984; Rohleder et al. 2004). Saliva α -amylase activity was significantly
419 higher at 1 h post-exercise on both caffeine trials compared with placebo. However, only the

420 large single dose caffeine trial (1xCAF) showed a significantly higher α -amylase secretion
421 rate at 1 h post-exercise compared with placebo. As such this may explain why in the present
422 study this was the only caffeine trial to attenuate the exercise-induced increase in both the
423 number of antigen-stimulated NK cells expressing CD69 and their intensity of CD69
424 expression following high intensity shuttle running. Large (6 and 9 mg·kg⁻¹), but not small (3
425 mg·kg⁻¹), doses of caffeine have been shown to increase plasma epinephrine concentration in
426 response to high intensity exercise (Graham and Spriet 1995; Walker et al. 2006). Therefore,
427 it could perhaps be suggested that there may be an epinephrine threshold, above which
428 epinephrine produces inhibitory effects upon NK cell CD69 expression. However, as plasma
429 epinephrine concentrations were not directly determined in this study, any explanation as to
430 how the large bolus dose of caffeine attenuated the exercise-induced increase in antigen-
431 stimulated NK cell CD69 expression following exercise is only speculation and as such is a
432 limitation of this study.

433

434 The increase in number of antigen-stimulated NK cells expressing CD69 following exercise
435 on PLA could be interpreted in a number of ways due to the multiple complex actions of
436 CD69. One could suggest that this increase may augment subsequent proliferation,
437 cytotoxicity and pro-inflammatory cytokine release that would appear to favour a pro-
438 inflammatory response via the actions of CD69 as a co-stimulatory receptor (Borrego et al.
439 1999). However, CD69 has also been shown to act as a negative regulator, downregulating
440 the ability of NK cells to lyse target cells due to the production of TGF- β (Esplugues et al.
441 2003). As such the increase in the number of NK cells expressing CD69 in response to
442 antigen may act as a regulatory response. However, given that TGF- β release by CD69⁺ NK
443 cells was not determined it is difficult to ascertain the exact role of CD69 in this study.
444 Future *in vitro* work to determine the nature of the response (e.g. assessment of TGF- β

445 release) would provide greater insight regarding to the physiological nature and implications
446 of these findings.

447

448 Alternatively, it could be argued that as participants were habitual caffeine users, the effects
449 of caffeine on antigen-stimulated NK cell CD69 expression in response to prolonged high
450 intensity exercise in this study may have resulted from participants' tolerance to the effects of
451 caffeine. It has been demonstrated that tolerance to some of the effects of caffeine can
452 develop quite quickly in habitual caffeine users (reviewed in Fredholm et al. 1999). Studies
453 both in rats and humans suggest that following chronic caffeine intake (~14 days) A₁ and A_{2A}
454 adenosine receptors are upregulated leading to an increased sensitivity to adenosine
455 (Johansson et al. 1997; Varani et al. 2005). Therefore, as participants were only required to
456 abstain from caffeine overnight, caffeine habituation may have contributed towards the
457 findings that one large bolus dose of caffeine attenuated the exercise-induced increase in
458 antigen-stimulated NK cell CD69 expression 1 h following high intensity shuttle running yet
459 small repeated doses of caffeine had little effect at all. It should be noted that the mechanisms
460 discussed here are unlikely to occur exclusively; therefore these findings are likely to be the
461 net result of several positive and negative influences.

462

463 The issue of tolerance could also help explain why the findings of the present study contrast
464 with our previous results when caffeine ingestion (2 and 6 mg·kg⁻¹) increased antigen
465 stimulated NK cell CD69 expression 1 h following 90 min high intensity exercise compared
466 with placebo (Fletcher and Bishop in press). Tolerance to caffeine dissipates after its
467 discontinuation, with resensitization to caffeine usually occurring within 2-3 days of
468 abstention (Benowitz et al. 1995; Varani et al. 2005). Our previous work employed a 60 h
469 caffeine abstention period and as such likely controlled for any influence of caffeine

470 tolerance. The mode of exercise in the present study was also different to that used in our
471 previous work (intermittent running and continuous cycling, respectively) and may have
472 influenced caffeine metabolism and as such caffeine's effects. However, this seems unlikely
473 as Graham and Spriet (1991) have reported no difference in caffeine metabolism or plasma
474 epinephrine concentration between running and cycling to exhaustion. In addition, serum
475 caffeine concentrations immediately following 90 min continuous cycling (Fletcher and
476 Bishop 2010) and intermittent running (present study) with prior ingestion of $6 \text{ mg}\cdot\text{kg}^{-1}$ body
477 mass caffeine showed comparable values (continuous cycling, $44 \text{ }\mu\text{M}$; intermittent running,
478 $43 \text{ }\mu\text{M}$).

479

480 One limitation of this study was the absence of a resting trial to determine if caffeine acted on
481 antigen-stimulated NK cell CD69 expression without the influence of exercise. Initial pilot
482 work from our group that looked at NK cell responses to caffeine at rest between 08:30 h and
483 12:00 h suggests that caffeine at doses of 2 or $6 \text{ mg}\cdot\text{kg}^{-1}$ body mass ingested in one bolus dose
484 at 08:30 h have little effect on antigen-stimulated NK cell CD69 expression up until 12:00 h.

485

486 In conclusion, the findings of the present study suggest that exercise induced an increase in
487 the number of antigen-stimulated NK cells expressing CD69 as well as their intensity of
488 CD69 expression 1 h following 90 min shuttle running that was attenuated by one large bolus
489 dose ($6 \text{ mg}\cdot\text{kg}^{-1}$) of caffeine ingested 1 h prior to exercise. In contrast, small doses ($2 \text{ mg}\cdot\text{kg}^{-1}$)
490 of caffeine ingested throughout the day to model a more typical pattern of caffeine
491 consumption had little effect on antigen-stimulated NK cell CD69 expression. It should be
492 noted that the attenuations seen with one large bolus dose of caffeine at no point fell below
493 pre-supplement values and as such suggests that caffeine does not depress antigen-stimulated
494 NK cell CD69 expression following 90 min of high intensity shuttle running.

495

496 **Acknowledgements**

497 The authors would like to thank Aled Hill, Andrew Shaw, Victoria Woolcott and Andrew
498 Mariani for their help in the data collection.

499

500 **Ethical Standards**

501 The authors declare that the experiments comply with the current laws of the U.K.

502

503 **Conflict of Interest**

504 The authors declare that they have no conflict of interest.

505

506 **References**

507 Anderson LC, Garrett JR, Johnson DA, Kauffman DL, Keller PJ, Thulin A (1984) Influence
508 of circulating catecholamines on protein secretion into rat parotid saliva during
509 parasympathetic stimulation. *J Physiol* 352:163-171

510 Andoniou CE, Andrews DM, Degli-Esposti MA (2006) Natural killer cells in viral infection:
511 more than just killers. *Immunol Rev* 214:239-250

512 Benowitz NL, Jacob P, Mayan H, Denaro C (1995) Sympathomimetic effects of paraxanthine
513 and caffeine in humans. *Clin Pharmacol Ther* 58:684-691

514 Benschop RJ, Schedlowski M, Wienecke H, Jacobs R, Schmidt RE (1997) Adrenergic control
515 of natural killer cell circulation and adhesion. *Brain Behav Immun* 11:321

516 Bishop NC, Fitzgerald C, Porter PJ, Scanlon GA, Smith AC (2005) Effect of caffeine
517 ingestion on lymphocyte counts and subset activation in vivo following strenuous cycling.
518 *Eur J Appl Physiol* 93:606-613

519 Bishop NC, Gleeson M, Nicholas CW, Ali A (2002) Influence of carbohydrate
520 supplementation on plasma cytokine and neutrophil degranulation responses to high intensity
521 intermittent exercise. *Int J Sport Nutr Exerc Metab* 12:145-156

522 Bishop NC, Walker GJ, Scanlon GA, Richards S, Rogers E (2006) Salivary IgA responses to
523 prolonged intensive exercise following caffeine ingestion. *Med Sci Sports Exerc* 38:513-519

- 524 Borrego F, Robertson MJ, Ritz J, Peña J, Solana R (1999) CD69 is a stimulatory receptor for
525 natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor.
526 *Immunology* 97:159-165
- 527 Cole AS, Eastoe JE (1988) *Biochemistry and Oral Biology*. London:Wright 477
- 528 Dill DB, Costill DL (1974) Calculation of percentage changes in volumes of blood, plasma,
529 and red-cells in dehydration. *J Appl Physiol* 37:247-248
- 530 Esplugues E, Sancho D, Vega-Ramos J et al (2003) Enhanced antitumor immunity in mice
531 deficient in CD69. *J Exp Med* 197:1093-1106
- 532 Fletcher DK, Bishop NC (2010) Caffeine ingestion and antigen-stimulated human
533 lymphocyte activation after prolonged cycling. *Scand J Med Sci Sports* DOI: 10.1111/j.1600-
534 0838.2010.01223.x, in press.
- 535 Fletcher DK, Bishop NC (in press) Effect of a high and low dose of caffeine on antigen-
536 stimulated human natural killer cell activation after prolonged cycling. *Int J Sports Nutr Exerc*
537 *Metab*
- 538 Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the
539 brain with special reference to factors that contribute to its widespread use. *Pharmacol*
540 *Reviews* 51:83
- 541 Graham TE (2001) Caffeine and exercise: Metabolism, endurance and performance. *Sports*
542 *Med*. 31:785-807
- 543 Graham TE, Spriet LL (1991) Performance and metabolic responses to a high caffeine dose
544 during prolonged exercise. *J Appl Physiol* 71:2292-2298
- 545 Graham TE, Spriet LL (1995) Metabolic, catecholamine, and exercise performance responses
546 to various doses of caffeine. *J Appl Physiol* 78
- 547 Heatherley SV, Mullings EL, Tidbury MA, Rogers PJ (2006) Caffeine consumption among a
548 sample of UK adults. *Appetite* 47:266
- 549 Johansson B, Georgiev V, Lindstrom K, Fredholm BB (1997) A₁ and A_{2A} adenosine receptors
550 and A₁ mRNA in mouse brain: Effect of long-term caffeine treatment. *Brain Res* 762:153-162
- 551 Kappel M, Tvede N, Galbo H et al (1991) Evidence that the effect of physical exercise on NK
552 cell activity is mediated by epinephrine. *J Appl Physiol* 70:2530-2534
- 553 Nieman D, Henson D, Gojanovich G et al (2007) Immune changes: 2 h of continuous vs.
554 intermittent cycling. *Int J Sports Med* 28:625
- 555 Nieman DC (2000) Is infection risk linked to exercise workload? *Med Sci Sports Exerc*
556 32:S406
- 557 Priebe T, Platsoucas CD, Nelson JA (1990) Adenosine receptors and modulation of natural
558 killer cell activity by purine nucleosides. *Cancer Res* 50:4328-4331

- 559 Ramsbottom R, Brewer J, Williams C (1988) A progressive shuttle run test to estimate
560 maximal oxygen uptake. *Br J Sports Med* 22:141-144
- 561 Raskovalova T, Lokshin A, Huang X, Jackson EK, Gorelik E (2006) Adenosine-mediated
562 inhibition of cytotoxic activity and cytokine production by IL-2/NKp46-activated NK cells:
563 Involvement of protein kinase A isozyme I (PKA I). *Immunol Res* 36:91-100
- 564 Rohleder N, Nater UM, Wolf JM, Ehlert U, Kirschbaum C (2004) Psychosocial stress-
565 induced activation of salivary alpha amylase. An indicator of sympathetic activity? *Ann N Y*
566 *Acad Sci* 1032:258-263
- 567 Shephard RJ (2003) Adhesion molecules, catecholamines and leucocyte redistribution during
568 and following exercise. *Sports Med* 33:261-284
- 569 Sancho D, Gómez M, Viedma F et al (2003) CD69 downregulates autoimmune reactivity
570 through active transforming growth factor- β production in collagen induced arthritis. *J Clin*
571 *Invest* 112:872-882
- 572 Sancho D, Gómez M, Sánchez-Madrid F (2005) CD69 is an immunoregulatory molecule
573 induced following activation. *Trends Immunol* 26:136-140
- 574 Shimamiya T, Wakabayashi S, Terada N (2003) Effects of adrenaline and cortisone on the
575 early activation of lymphocytes. *Biol Sci Space* 17:221-222
- 576 Timmons BW, Tarnopolsky MA, Sinder DP, Bar-Or O (2006) Puberty effects of NK cell
577 responses to exercise and carbohydrate intake in boys. *Med Sci Sports Exerc* 38:867-874
- 578 Varani K, Portaluppi F, Gessi S et al (2005) Caffeine intake induces an alteration in human
579 neutrophil A2A adenosine receptors. *Cell Mol Life Sci* 62:2350-2358
- 580 Vizi E, Huszar E, Csoma Z et al (2002) Plasma adenosine concentration increases during
581 exercise: A possible contributing factor in exercise-induced bronchoconstriction in asthma. *J*
582 *Allergy Clin Immunol* 109:446-448
- 583 Walker GJ, Dziubak A, Houghton L, Prendergast C, Lim L, Bishop NC (2008) The effect of
584 caffeine ingestion on human neutrophil oxidative burst responses following time-trial cycling.
585 *J Sports Sci* 26:611-619
- 586 Walker GJ, Finlay O, Griffiths H, Sylvester J, Williams M, Bishop NC (2007)
587 Immunoendocrine response to cycling following ingestion of caffeine and carbohydrate. *Med*
588 *Sci Sports Exerc* 39:1554-1560
- 589 Walker GJ, Caudwell P, Dixon N, Bishop NC (2006) The effect of caffeine ingestion on
590 neutrophil oxidative burst responses following prolonged cycling. *Int J Sport Nutr Exerc*
591 *Metab* 16:24-35
- 592 Ziegler SF, Ramsdell F, Alderson MR (1994) The activation antigen CD69. *Stem Cells*
593 12:456
- 594

595 **Figure captions**

596 **Fig. 1** Schematic representation of the trial protocol

597 **Fig. 2** Schematic representation of the Loughborough Intermittent Shuttle Running Test
598 (LIST). Adapted from Bishop et al. 2002


599 **Fig. 3** Serum caffeine concentrations during PLA, 3xCAF and 1xCAF trials. * significantly
600 higher than PLA (P<0.01). ** significantly higher than PLA and 3xCAF (P<0.01).
601 § significantly higher than PLA and 1xCAF (P<0.01). † significantly higher than pre-
602 supplement within trial (P<0.01). Values are means \pm SD

603 **Fig. 4** Number of (a) unstimulated (b) 1:4000 antigen-stimulated, (c) 1:8000 antigen-
604 stimulated CD3⁻CD56⁺ NK cells expressing CD69 within the circulating lymphocyte
605 population during PLA, 3xCAF and 1xCAF trials. * significantly lower than PLA (P<0.05);
606 † significantly higher than pre-supplement within trial (P<0.01). Values are means + SD

607 **Fig. 5** Geometric Mean Fluorescence Intensity of CD69 expression on (a) unstimulated (b)
608 1:4000 antigen-stimulated, (c) 1:8000 antigen-stimulated CD3⁻CD56⁺ NK cells within the
609 circulating lymphocyte population during PLA, 3xCAF and 1xCAF trials. * significantly
610 lower than PLA and 3xCAF (P<0.05); † significantly higher than pre-supplement within trial
611 (P<0.01). Values are means + SD and are expressed as a percentage of the pre-supplement
612 value

613


614 Fig. 1



620


621
622

623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655




656
657
658

659 Fig. 3
660




661
662

Fig. 4a



663

4b



664

4c




665
666

Fig. 5a




667

5b



668

5c

669
670

671 Table 1 Saliva caffeine concentration, flow rate, α -amylase activity and secretion rate during PLA, 3xCAF and
 672 1xCAF trials

| | 09:00 h (Pre-supplement) | 10:00 h | 12:00 h | 15:00 h | 16:00 h (Pre-exercise) | 17:45 h (Post-exercise) | 18:45 h (1 h post-exercise) |
|--|-----------------------------|-----------|-----------|-----------|---------------------------|----------------------------|--------------------------------|
| Saliva caffeine concentration ($\mu\text{mol}\cdot\text{L}^{-1}$) | | | | | | | |
| PLA | 1 (1) | 1 (1) | 1 (1) | 1 (1) | 0 (0) | 0 (0) | 0 (0) |
| 3xCAF | 1 (1) | 10 (4)*‡ | 8 (2)*‡ | 14 (3)*‡ | 15 (3)*‡ | 20 (5)*‡ | 19 (4)*‡ |
| 1xCAF | 1 (1) | 0 (0) | 0 (0) | 1 (1) | 2 (2) | 30 (4)*§ | 27 (4)*§ |
| Saliva flow rate ($\mu\text{l}\cdot\text{min}^{-1}$)^{a,b} | | | | | | | |
| PLA | 441 (268) | 549 (252) | 543 (180) | 567 (203) | 572 (200) | 484 (171) | 683 (248) |
| 3xCAF | 431 (216) | 571 (254) | 586 (185) | 591 (294) | 585 (252) | 467 (209) | 656 (286) |
| 1xCAF | 423 (241) | 575 (240) | 546 (203) | 566 (165) | 642 (223) | 520 (203) | 698 (225) |
| Saliva α-amylase activity ($\text{U}\cdot\text{ml}^{-1}$) | | | | | | | |
| PLA | 392 (257) | 439 (243) | 793 (416) | 967 (373) | 827 (373) [†] | 1456 (530) [†] | 867 (494) [†] |
| 3xCAF | 306 (271) | 608 (346) | 845 (319) | 936 (316) | 997 (313)** [†] | 1719 (527) [†] | 1098 (430)** [†] |
| 1xCAF | 368 (299) | 545 (290) | 905 (442) | 925 (345) | 1023 (369)** [†] | 1615 (457) [†] | 1196 (402)** [†] |
| Saliva α-amylase secretion rate ($\text{U}\cdot\text{min}^{-1}$) | | | | | | | |
| PLA | 174 (167) | 234 (150) | 444 (284) | 569 (433) | 487 (323) [†] | 695 (343) [†] | 580 (391) [†] |
| 3xCAF | 138 (151) | 239 (291) | 526 (353) | 570 (357) | 587 (357) [†] | 810 (470) [†] | 742 (452) [†] |
| 1xCAF | 157 (154) | 314 (192) | 497 (293) | 494 (188) | 660 (327) [†] | 812 (338) [†] | 804 (289)** [†] |

673

674 Values are means (SD)

675 * P<0.01, ** P<0.05: significantly higher than PLA

676 ‡ significantly higher than 1xCAF, P<0.01

677 § significantly higher than 3xCAF, P<0.01

678 [†] P<0.01: significantly higher than pre-supplement within trial679 ^a main effect for time; significantly higher than pre-supplement at all other time-points, all P<0.01 except for
 680 post-exercise P<0.05681 ^b main effect for time; significantly lower than pre-exercise at post-exercise, P<0.01

682

683 Table 2 Number of circulating lymphocytes and CD3⁺CD56⁺ cells within the circulating lymphocyte
 684 population during PLA, 3xCAF and 1xCAF trials
 685
 686

| | Pre-supplement | Pre-exercise | Post-exercise | 1 h post-exercise |
|---|----------------|---------------------------|----------------------------|-------------------|
| Lymphocytes (x10⁹ cells.L⁻¹)^a | | | | |
| PLA | 2.10 (0.50) | 2.10 (0.50) | 2.90 (0.80) | 2.10 (0.50) |
| 3xCAF | 2.10 (0.70) | 2.00 (0.50) | 3.10 (1.00) | 1.90 (0.50) |
| 1xCAF | 2.10 (0.40) | 2.10 (0.40) | 3.20 (0.80) | 1.90 (0.60) |
| CD3⁺CD56⁺ cells (x10⁹ cells.L⁻¹) | | | | |
| PLA | 0.26 (0.08) | 0.30 (0.09) | 0.53 (0.16) [†] | 0.25 (0.07) |
| 3xCAF | 0.28 (0.09) | 0.35 (0.10) ^{††} | 0.70 (0.22) ^{**†} | 0.25 (0.07) |
| 1xCAF | 0.29 (0.11) | 0.36 (0.09) ^{††} | 0.80 (0.32) ^{*†} | 0.27 (0.09) |

703
 704
 705
 706
 707
 708
 709
 710
 711

Values are means (SD)

* P<0.01; ** P<0.05, significantly higher than PLA

[†] P<0.01; ^{††} P<0.05, significantly higher than pre-supplement within trial

^a main effect for time; significantly higher than pre-supplement at post-exercise, P<0.01